GlassScriptPhysician profile
Ronald J Ordas
NPI 1932450426
$8,266.57
in general payments reported to CMS, 2019-2025
31 companies · $2,349 in 2025
The $2,349 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $737 · 2022: $1,342 · 2023: $2,093 · 2024: $1,745 · 2025: $2,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,187.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,787.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $646.53 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Edwards Lifesciences Corporation | $633.14 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $534.64 | 2022-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Janssen Pharmaceuticals, INC | $503.95 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $441.67 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $429.14 | 2021-2025 | Lifevest |
| Amgen INC. | $348.76 | 2021-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $334.57 | 2023-2025 | Uptravi, Opsumit |
| Pfizer INC. | $312.07 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $258.79 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $257.32 | 2021-2025 | Mitraclip, Aveir, Portico |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.07 | 2021-2025 | Jardiance |
| Recor Medical INC | $203.65 | 2024 | Paradise Renal Denervation System |
| Alnylam Pharmaceuticals INC. | $184.62 | 2023-2025 | Amvuttra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $155.66 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $141.44 | 2022-2024 | |
| Medtronic, INC. | $130.37 | 2021 | |
| Esperion Therapeutics, INC. | $126.69 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $121.78 | 2024-2025 | Wegovy |
| Tactile Systems Technology INC | $120.75 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Atricure, INC. | $118.08 | 2023-2025 | Atriclip Laa Exclusion System |
| Bayer Healthcare Pharmaceuticals INC. | $60.99 | 2025 | |
| Daiichi Sankyo INC. | $42.77 | 2023 | Injectafer |
| Itamar Medical INC | $36.07 | 2021-2022 | |
| Lilly USA, LLC | $28.68 | 2025 | Zepbound, Mounjaro |
| Siemens Medical Solutions USA, INC. | $26.84 | 2025 | Artis Q Floor |
| Regeneron Healthcare Solutions, INC. | $24.41 | 2025 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.81 | 2024 | |
| Vivaquant INC, Dba Rhythm Express | $11.80 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ordas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.